Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, B-Cell 19Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Non-Hodgkin 13Recurrence 12Multiple Myeloma 11Burkitt Lymphoma 11Lymphoma, Mantle-Cell 8Lymphoma 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 7Pancreatic Neoplasms 6Lymphoma, Follicular 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasms 5Leukemia 5Glioma 5Colorectal Neoplasms 5Stomach Neoplasms 4Leukemia, B-Cell 4Hematologic Neoplasms 4Neoplasm, Residual 3Nasopharyngeal Carcinoma 3Melanoma 3Esophageal Neoplasms 3Breast Neoplasms 3Simpson-Golabi-Behmel syndrome 2Sarcoma, Synovial 2Sarcoma, Ewing 2Rhabdomyosarcoma 2

Interventions

tislelizumab 2Oxaliplatin 2tremelimumab 1olaparib 1durvalumab 1apatinib 1Tegafur 1Immunotherapy, Adoptive 1Dacarbazine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunotherapy × Immunotherapy, Adoptive × Clear all
NCT05354375 2022-04-29

Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

The Affiliated Hospital of Xuzhou Medical University

Phase 1 Recruiting
20 enrolled

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡